Sears studies cellular signaling pathways that control tumor cell behavior, which contributed to development of a drug that dramatically inhibits tumor growth and significantly extends survival in mouse pancreas cancer models.
Maryland Proton Treatment Center Names New Medical Director
Charles B. Simone, II, MD, has been named the new Medical Director of the Maryland Proton Treatment Center (MPTC) beginning in November 2016.
In this position, Simone will continue to define and implement processes ensuring that MPTC is integrated into the radiation oncology program and the University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center/System, and the University of Maryland School of Medicine (UM SOM).
He will also participate in development of clinical trials and research protocols; assume a leadership role within the Maryland Proton Alliance, a partnership between UM SOM and MPTC; and provide expertise in refining criteria for proton therapy patient selection within the department's clinical practice guidelines.
Prior to coming to MPTC, Simone was Co-Director of the Penn Mesothelioma and Pleural Program at the University of Pennsylvania Health System. He was also Associate Professor in the Department of Radiation Oncology at the University of Pennsylvania School of Medicine and the Thoracic Oncology Service Chief for the University of Pennsylvania Health System.
He is nationally recognized as an expert for the use of proton therapy in the treatment of thoracic malignancies, development of clinical trial strategies, and innovative research in thoracic radiation oncology. He chairs the Lung Committee of the Proton Collaborative Group, a national cooperative research coalition, is a member of the American Society for Radiation Oncology Lung Resource Panel, and a member of the NRG Oncology Lung Cancer Committee and the NRG Oncology Radiation Oncology Committee.
In his research, Simone has worked extensively on radiation therapy for thoracic tumors. He has coauthored more than 150 peer-reviewed manuscripts, chapters, reviews, and editorials, and has presented more than 100 scientific lectures to national and international audiences.
Cancer Prevention Expert Named to HHS 2018 Advisory Committee
Anne McTiernan, MD, PhD, a breast cancer epidemiologist and cancer prevention expert at Fred Hutchinson Cancer Research Center, Seattle, has been appointed to the 2018 Physical Guidelines Advisory Committee of the U.S. Department of Health and Human Services.
She is among 17 nationally recognized experts in physical activity and health to serve on the committee. Over the next 2 years, the committee will examine current scientific evidence on the link between physical activity and health outcomes, and ultimately will submit evidence-based recommendations in a scientific advisory report to the secretary of HHS. These recommendations will help inform the second edition of the Physical Activity Guidelines for Americans, which is expected to be released in 2018.
McTiernan is a member of the Public Health Sciences Division at Fred Hutch, where cancer prevention is a major focus of research. McTiernan has led groundbreaking randomized clinical trials that have shown regular moderate aerobic exercise (such as brisk walking for 30 minutes a day) significantly reduces risk factors for breast cancer in women and colon cancer in men.
Cancer Surgeon Named Finalist for 2016 Giants of Cancer Care Recognition
Norman Wolmark, MD, an internationally recognized cancer surgeon and Medical Director of Breast Surgical Oncology, Cancer Research and Clinical Trials at Allegheny Health Network (AHN), has been named a finalist in the 2016 Giants of Cancer Care recognition program. The finalists were selected for their achievements, talents, and compassionate care to patients and families in oncology research and clinical practice.
Wolmark is Chairman of the NSABP Foundation and Chair and principal investigator of NCI-funded NRG Oncology. The NSABP has a nearly 60-year history of conducting groundbreaking research studies in breast and colorectal cancer, enrolling more than 110,000 men and women in clinical trials, and coordinating research at nearly 700 major medical centers, university hospitals, large oncology practice groups, and health maintenance organizations in the U.S., Canada, and Ireland.
A member of a number of professional associations and organizations including the American Surgical Association, Wolmark is widely published, with more than 400 scientific journal articles and book chapters in print. He is a widely sought-after speaker and lecturer in his field and serves on the editorial board of The Journal of Clinical Oncology, JAMA, and The Lancet, on numerous advisory boards, and as an advisor to oncology programs, societies, and institutes throughout the U.S. and abroad.
Wolmark is a finalist in the breast cancer category along with Larry Norton, MD, of Memorial Sloan Kettering Cancer Center; Sandra Swain, MD, of Washington Cancer Institute, Georgetown University; Martine Piccart, MD, PhD, Universite Libre de Bruxelles; and Umberto Veronisi, MD, European Institute of Oncology.
Now in its fourth year, the Giants of Cancer Care recognition program celebrates the achievements of leading physicians and researchers who have devoted their time, talent, and resources to improving care for the many patients and their families affected by cancer. Their discoveries have propelled the field forward and established the building blocks for future advances.
Unlike other programs, the Giants of Cancer Care honors specialists nominated by their peers. Recipients demonstrate the qualities that distinguish this award from others: unlimited selflessness, compassion for their patients, and a desire to understand and develop life-changing treatments against a disease that affects so many.
The winners will be announced at the 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow, Nov. 9-11, at the New York Marriott Marquis.
Society for Epidemiologic Research Elects President
Andrew Olshan, PhD, Associate Director of Population Sciences and co-leader of the epidemiology program at UNC Lineberger Comprehensive Cancer Center, Chapel Hill, has been elected President of the Society for Epidemiologic Research. He currently is serving as President-Elect and will become President of the organization in July 2017.
Olshan is a leading expert in the molecular epidemiology of cancers of the head and neck and evaluation of risk factors for childhood cancer as well as reproductive, perinatal, and pediatric epidemiology.
He is the Barbara Sorenson Hulka Distinguished Professor and Chair of the Department of Epidemiology at the UNC Gillings School of Global Public Health and a Professor of otolaryngology and head and neck surgery at the UNC School of Medicine. Olshan also is the principal investigator of the Carolina Head and Neck Cancer Study, co-principal investigator for the Carolina Breast Cancer Study, and he leads the North Carolina Center for Birth Defects Research and Prevention.
WVU Cancer Institute Fellow Receives ASCO Merit Award
Mark Knestrick, MD, a recent graduate of WVU's Hematology/Oncology Fellowship Program, received a 2016 Conquer Cancer Foundation of ASCO Merit Award. The Merit Award is open to oncology trainees who are first authors on abstracts selected for presentation at an ASCO scientific meeting, including the 2016 ASCO Annual Meeting in Chicago where Knestrick presented his research: Benefits of physician orders for scope of treatment (POST) forms on end-of-life care in cancer patients: Insights from the West Virginia registry (Abstract 10006).
The research indicated that POST forms when compared to traditional advance directives (living will or medical power of attorney) were associated with a greater achievement of quality metrics for end-of-life care in cancer patients.
Knestrick teamed up with Alvin H. Moss, MD, of WVU Medicine and Section Chief of Supportive Care Services and Sandra Pedraza, MD, also of Supportive Care Services, on the research project.
This WVU research was also selected for presentation and discussion at the Best of ASCO meetings, which highlight the most cutting-edge science and education from the ASCO Annual Meeting.
Share Your News!
Send information and photos for this column to firstname.lastname@example.orgWolters Kluwer Health, Inc. All rights reserved.
More on ONCOLOGY-TIMES.com...